BioCorRx Shares Financial Results for Q2 2017

BioCorRx (OTCQB:BICX) released their financial report for the second quarter of 2017 and provided a business update to shareholders.

As quoted in the press release:

Brady Granier, President, CEO, and Director, stated, “We are pleased to report a 12% increase in revenue for the second quarter ended June 30, 2017. The increase in revenue is due to the increased number of clinics, as well as patients treated at clinics already licensed to offer our BioCorRx Recovery Program. In July, we entered into agreements with centers in three different states that will be implementing the BioCorRx Recovery Program. Our program is a non-addictive, medication-assisted treatment (MAT) program that combines a naltrexone implant with a proprietary counseling program and peer support specifically tailored for the treatment of alcoholism and opioid use disorder. In South Florida, we are now working with Hope Recovery and Wellness in West Palm Beach, which will be the first center in that area to implement the BioCorRx Recovery Program. EnLite™ Clinics is the first center to introduce our program in Ohio (at three locations), which is considered by many to be the epicenter of the opioid crisis. Lastly, we announced that Serrano KVAC clinic, an affiliate of the Serrano Kidney and Vascular Access Center of California, in conjunction with Serrano KVAC’s partner CereCare, LLC, will implement the BioCorRx Recovery Program for the Hispanic market in Los Angeles, California. This marks the first clinic offering our program specifically for the Hispanic market.”

Click here to read the full press release.

Get the Latest Pharmaceutical Investing Stock Information

Get the latest information about companies associated with Pharmaceutical Investing delivered directly to your inbox.


By selecting company or companies above, you are giving consent to receive email from those companies. And remember you can unsubscribe at any time.

Are You Aware of the FDA's Plans for 2018?

Find out what's going on in our new report

Leave a Reply